Only 25% of African-American men ages 60 to 69 years undergo PSA screening and 36% receive annual digital rectal exams, while just under 50% of African-Americans at high risk for the disease (those with a family history) undergo PSA tests and 38% receive DREs, according to a study published in Cancer (2006; 106:796-803).
Only 25% of African-American men ages 60 to 69 years undergo PSA screening and 36% receive annual digital rectal exams, while just under 50% of African-Americans at high risk for the disease (those with a family history) undergo PSA tests and 38% receive DREs, according to a study published in Cancer (2006; 106:796-803). By comparison, 81% of Caucasian males of the same age undergo PSA tests and 68% receive DREs.
Prior research has shown that African-American men have a 50% higher incidence of prostate cancer and more than double the mortality rate of Caucasian men. This research further suggests a glaring health disparity with access to health care and economics as key factors, said lead author Sally Weinrich, MD, of the Medical College of Georgia, Augusta.
“African-American men have the right to be informed about prostate cancer screening options,” she said. “We need additional research to study the reasons why African-American men with a positive family history have lower screening rates than African-American men in general.”
A separate study to be published in the March 15 issue of Cancer suggests that race plays a minor role in prostate cancer survival, and that the most important explaining disparities in outcomes were education, community poverty, and income levels. Age, disease stage, and treatment method also independently impacted outcome.
The researchers found that in men with local or regional prostate cancer, lower socioeconomic status was significantly associated with decreased survival, even after controlling for other patient/tumor characteristics and treatment. The study also identified “racial and ethnic disparities in survival, but these disparities reduced substantially after controlling for socioeconomic factors,” according to the authors, led by Xianglin L. Du, PhD, of the University of Texas School of Public Health, Houston.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
2 Commerce Drive
Cranbury, NJ 08512